How Many Units Is 7.5 mg of Tirzepatide?
Between 12.5 and 225.23 units, depending entirely on how concentrated your vial is — and that is something you decided when you chose your water volume. Enter your own vial below for the exact figure.
Written by Kashif Khan, who builds and maintains this site and is not a clinician. Every figure links to its primary source.
Why there is no single answer
A syringe unit measures volume, not mass: one unit is 1/100 of a millilitre. So Tirzepatide at 7.5 mg lands on a different mark at every concentration. Find the row matching the vial and water volume you actually used.
7.5 mg at every concentration
ISO 8537 fixes the U-100 scale, so 100 units is 1 mL on every insulin syringe sold for human use and the conversion is a division rather than a lookup. The divisor is your concentration. Each row below is a vial you might plausibly be holding rather than an abstract mg/mL figure, because nobody owns “12.5 mg/mL” — they own a 25 mg vial and a syringe of water.
| Concentration | A vial that gives it | Draw | Units (U-100) | Reading it |
|---|---|---|---|---|
| 3.33 mg/mL | 10 mg vial + 3 mL | 2.252 mL | 225.23 | Over 100 units — more than one U-100 barrel holds |
| 5 mg/mL | 10 mg vial + 2 mL | 1.5 mL | 150 | Over 100 units — more than one U-100 barrel holds |
| 6.67 mg/mL | 20 mg vial + 3 mL | 1.124 mL | 112.44 | Over 100 units — more than one U-100 barrel holds |
| 10 mg/mL | 10 mg vial + 1 mL | 0.75 mL | 75 | Printed on 0.3 and 0.5 mL barrels; between marks on a 1 mL |
| 13.33 mg/mL | 40 mg vial + 3 mL | 0.563 mL | 56.26 | Between the marks on every standard barrel |
| 15 mg/mL | 30 mg vial + 2 mL | 0.5 mL | 50 | Printed mark on every U-100 barrel |
| 20 mg/mL | 20 mg vial + 1 mL | 0.375 mL | 37.5 | Half unit — needs a half-unit 0.3 mL barrel |
| 30 mg/mL | 30 mg vial + 1 mL | 0.25 mL | 25 | Printed on 0.3 and 0.5 mL barrels; between marks on a 1 mL |
| 40 mg/mL | 40 mg vial + 1 mL | 0.188 mL | 18.75 | Between the marks on every standard barrel |
| 60 mg/mL | 60 mg vial + 1 mL | 0.125 mL | 12.5 | Half unit — needs a half-unit 0.3 mL barrel |
The dose is fixed across that table and the volume moves. Doubling the concentration halves the units — which is the practical reason to care about water volume at all: it is the only lever you have over how readable the mark is. Note that at 3.33 mg/mL, 5 mg/mL, and 6.67 mg/mL this dose exceeds 100 units, so it does not fit in a single 1 mL U-100 barrel.
Does any approved label use 7.5 mg?
Yes — one approved schedule has a 7.5 mg step. The table places the figure on every one of those ladders, because the useful question is not only whether a label uses it but how far it is from one that does: a figure that lands on a step came from something checkable, one that falls between steps or above every maximum came from somewhere else.
| Schedule | Starts at | Maximum | 7.5 mg on this ladder |
|---|---|---|---|
| TirzepatideZepbound (weight management) | 2.5 mg | 15 mg | Labelled steptitration step, held at least 4 weeks |
| SemaglutideWegovy (weight management) | 0.25 mg | 7.2 mg | Above the 7.2 mg maximum — 1× the highest labelled dose |
| LiraglutideSaxenda (weight management) | 0.6 mg | 3 mg | Above the 3 mg maximum — 2.5× the highest labelled dose |
A match is a statement about the number, not about you: each of those schedules also fixes a starting dose, a minimum interval between increases and a maximum, and a syringe enforces none of them. The step it matches is the one to read on the label, not the one to draw.
The water volume that puts 7.5 mg on a round mark
Most people meet this question the other way round: they know the dose, they own a vial, and they want the syringe to read something they can stop the plunger on. Water is the only lever. For each vial size Tirzepatide is sold in, this is the volume that lands 7.5 mg exactly on 10, 20, 25 or 50 units, and how many draws of 7.5 mg the vial physically holds.
| Vial | Draws of 7.5 mg | 10 units | 20 units | 25 units | 50 units |
|---|---|---|---|---|---|
| 10 mg | 1 | 0.13 mLtoo little to measure | 0.27 mLtoo little to measure | 0.33 mL | 0.67 mL |
| 20 mg | 2 | 0.27 mLtoo little to measure | 0.53 mL | 0.67 mL | 1.33 mL |
| 30 mg | 4 | 0.4 mL | 0.8 mL | 1 mL | 2 mL |
| 40 mg | 5 | 0.53 mL | 1.07 mL | 1.33 mL | 2.67 mL |
| 60 mg | 8 | 0.8 mL | 1.6 mL | 2 mL | 4 mLover a 3 mL vial |
Greyed cells are volumes a standard vial will not hold or a syringe cannot measure. Between 20 and 50 units is where the published work on low-dose accuracy finds error smallest, so where two cells both fit, the one further right measures better. The draw count is arithmetic about a container — 8 draws of 7.5 mg from a 60 mg vial — and says nothing about whether 7.5 mg is anybody’s dose. That question belongs to the label and to whoever prescribed it, and the ladder table above tells you whether a label has an answer.
What the Tirzepatide label actually says
Approved 13 May 2022 as Mounjaro for type 2 diabetes, and 8 November 2023 as Zepbound for chronic weight management; Zepbound added obstructive sleep apnea on 20 December 2024. Every approved presentation is a ready-to-use sterile solution — no FDA-approved tirzepatide product is a lyophilised powder requiring reconstitution. Powder vials come from compounders, and the FDA declared the tirzepatide shortage resolved on 19 December 2024, ending the shortage basis for compounding it.
That matters here because the approved schedule is a fixed ladder, and the conversion above does not know where on it you are. The dosage may be increased in 2.5 mg increments after at least 4 weeks on the current dose. The label is explicit that the 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage. The maximum is 15 mg once weekly.
- 2.5 mg — starting dose, at least 4 weeks
- 5 mg — valid maintenance dose for weight reduction, at least 4 weeks
- 7.5 mg — titration step, at least 4 weeks
- 10 mg — maintenance; minimum maintenance dose for sleep apnea, at least 4 weeks
- 12.5 mg — titration step, at least 4 weeks
- 15 mg — maximum recommended dose
Full sourcing, the reconstitution calculator and the published evidence are on the Tirzepatide page.
Working it out yourself
Divide the milligrams of peptide in the vial by the millilitres of water you added. That is your concentration in mg/mL. Then divide 7.5 mg by that concentration to get the volume in millilitres, and multiply by 100 to turn millilitres into units on a U-100 syringe. Worked through at 10 mg/mL: 7.5 ÷ 10 = 0.75 mL, × 100 = 75 units. Two figures, one division, one multiplication. Every calculator doing this — including this one — is doing nothing more than that.
One honest caveat about the first step: the lyophilised cake occupies volume of its own, so the finished solution is marginally more than the water you added and the true concentration marginally lower than the division suggests. Measured displacement for lyophilised powders runs about 0.66 to 0.70 mL per gram of total solids, so a milligram-scale peptide vial displaces a few microlitres — well under one unit on a U-100 barrel, and finer than the barrel can be read. FDA labels state the nominal concentration without correcting for it either. The exception is a vial carrying a heavy bulking agent, where displacement can reach several percent.
For a fuller picture including the approved dosing schedule and its sources, see the Tirzepatide calculator.
Where this particular conversion goes wrong
- The syringe is not U-100. A U-40 veterinary barrel is fixed at 40 units per mL by 21 CFR 522.1160 and is still sold for animal insulin, which is labelled at that strength. The 75 unit mark you want holds 0.75 mL on a U-100 barrel and 1.875 mL on a U-40 one. Two and a half times the volume, from a barrel that looks the same. Both over- and under-dosing from exactly this substitution are documented in the published case literature.
- At 3.33 mg/mL and 5 mg/mL and 6.67 mg/mL it does not fit. 225.23 and 150 and 112.44 units is more than a 1 mL U-100 barrel holds. Splitting one dose across two injections to get around that is a choice about administration, not about arithmetic, and nothing on this page endorses it — the ordinary fix is to reconstitute with less water.
- One mark either way. At 10 mg/mL this dose is 75 units. Stopping one printed mark early or late is a 1% error on a 0.3 or 0.5 mL barrel and a 3% error on a 1 mL barrel printed in 2-unit steps — the same slip, twice the consequence, because the coarser barrel moves twice the volume per mark.
- Reading "7.5" as millilitres. 7.5 mg is 2.252 mL at the weakest concentration in the table and 0.125 mL at the strongest. The number never means millilitres on its own.
- Assuming the vial holds what the label says. Every figure here starts from the milligrams stated on your vial. For an FDA-approved product that figure is verified; for a compounded or grey-market vial nobody has checked it, and no calculator can. The arithmetic is exact — its input may not be.
Common questions
Sources
Every number on this page comes from one of the documents below. Where no reliable source exists, the page says so instead of filling the gap.
- FDA labelFDA / DailyMed· 2026-08MOUNJARO (tirzepatide) injection — FDA prescribing information
- FDA labelFDA / DailyMed· 2026-08ZEPBOUND (tirzepatide) injection — FDA prescribing information
- Published studyNew England Journal of Medicine· 2025Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5)
- GuidelineInternational Organization for Standardization· 2016-03ISO 8537:2016 — Sterile single-use syringes, with or without needle, for insulin (scope and requirements; full text not public)
- RegulatorFDA / Federal Register· 1998-05-13Removal of Regulations Regarding Certification of Drugs Composed Wholly or Partly of Insulin — 63 FR 26694 (the repealed insulin colour scheme, and U-40 no longer marketed)
- RegulatorUS Code of Federal Regulations / FDA21 CFR 522.1160 — Insulin (animal drugs): 40 international units (IU) per millilitre
- Published studyCase Reports in Endocrinology 2019;2019:7916435· 2019Barrera F, Murvelashvili N. Poorly controlled type 3c diabetes due to use of veterinarian insulin syringes
- Published studyDiabetology International 2024;15(3):544–549· 2024-05Kondo M, Saji R, Yamada Y, et al. Analysis of factors affecting the accuracy of low-dose insulin dosage using syringes and vials
- Published studyClinical Pediatrics 2004;43(1):69–74· 2004-01Keith K, Nicholson D, Rogers D. Accuracy and precision of low-dose insulin administration using syringes, pen injectors, and a pump
- Published studyBMJ Paediatrics Open· 2023Zheng L-Y et al. Displacement volume of reconstituted powder injections and its effect on dosing accuracy